Skip to main content
Erschienen in: Clinical and Experimental Nephrology 3/2012

01.06.2012 | Original Article

The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients

verfasst von: Mana Yahiro, Takahiro Kuragano, Aritoshi Kida, Rie Kitamura, Minoru Furuta, Yukiko Hasuike, Yoshinaga Otaki, Hiroshi Nonoguchi, Takeshi Nakanishi

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Hemoglobin (Hb) cycling in patients with renal anemia might be associated with a higher mortality rate. We investigated the association of factors relating serum ferritin and dose of erythropoiesis-stimulating agents (ESAs) with Hb levels.

Methods

We measured Hb and ferritin levels every month in 266 hemodialysis (HD) patients for 12 months.

Results

The standard deviation (SD) and residual SD (RSD) (liner regression of Hb or ferritin SD values) values of Hb were significantly correlated with ferritin SD or RSD values, respectively. The percentage achievement of target Hb in the target-ferritin group was significantly higher than in the high-amplitude fluctuation ferritin group. Ferritin SD and RSD values in patients with oral or no iron supplementation were significantly lower than those who received intravenous iron.

Conclusion

Iron storage varies over a relatively wide range in HD patients, and this variation is closely associated with Hb cycling. The stability of iron storage and ESA dosage is important for maintaining stable Hb levels.
Literatur
1.
Zurück zum Zitat Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, CHOIR Investigators, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.PubMedCrossRef Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, CHOIR Investigators, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.PubMedCrossRef
2.
Zurück zum Zitat Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, CREATE Investigators, et al. Normalizaiton of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.PubMedCrossRef Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, CREATE Investigators, et al. Normalizaiton of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.PubMedCrossRef
3.
Zurück zum Zitat Besarab A, Bolton WK, Browne JK, Egrie JC, Nissnoson AR, Okamoto DM, et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.PubMedCrossRef Besarab A, Bolton WK, Browne JK, Egrie JC, Nissnoson AR, Okamoto DM, et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.PubMedCrossRef
4.
Zurück zum Zitat Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–43.PubMedCrossRef Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–43.PubMedCrossRef
5.
Zurück zum Zitat Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: association with comorbidity, intercurrent events, and hospitalization. Clin J Am Soc Nephrol. 2006;1(6):1205–10.PubMedCrossRef Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: association with comorbidity, intercurrent events, and hospitalization. Clin J Am Soc Nephrol. 2006;1(6):1205–10.PubMedCrossRef
6.
Zurück zum Zitat Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18(12):3164–70.PubMedCrossRef Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18(12):3164–70.PubMedCrossRef
7.
Zurück zum Zitat Francisco ALM, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from hemoglobin variability to hyporesponsiveness. NDT Plus. 2009;Suppl 1:i18–26. Francisco ALM, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from hemoglobin variability to hyporesponsiveness. NDT Plus. 2009;Suppl 1:i18–26.
8.
Zurück zum Zitat Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009;20:479–87.PubMedCrossRef Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009;20:479–87.PubMedCrossRef
9.
Zurück zum Zitat Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidey Dis. 2008;52(5):897–906.CrossRef Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidey Dis. 2008;52(5):897–906.CrossRef
10.
Zurück zum Zitat Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl 2):25–9.PubMedCrossRef Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl 2):25–9.PubMedCrossRef
11.
Zurück zum Zitat Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end stage renal disease. Circulation. 2002;106:2212–7.PubMedCrossRef Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end stage renal disease. Circulation. 2002;106:2212–7.PubMedCrossRef
12.
Zurück zum Zitat Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32(5):439–46.PubMedCrossRef Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32(5):439–46.PubMedCrossRef
13.
Zurück zum Zitat Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999;14:2680–7.PubMedCrossRef Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999;14:2680–7.PubMedCrossRef
14.
Zurück zum Zitat Daugirdas JT, Greene T, Depner TA, Gotch FA, Star RA. Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney Int. 1999;56(5):1928–33.PubMedCrossRef Daugirdas JT, Greene T, Depner TA, Gotch FA, Star RA. Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney Int. 1999;56(5):1928–33.PubMedCrossRef
15.
Zurück zum Zitat Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. J Jpn Soc Dial Ther. 2008;41(10):661–716. Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. J Jpn Soc Dial Ther. 2008;41(10):661–716.
16.
Zurück zum Zitat Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65:1091–8.PubMedCrossRef Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65:1091–8.PubMedCrossRef
17.
Zurück zum Zitat Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, European Best Practice Guidelines Working Group, et al. Revised European Best Practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1–47.PubMedCrossRef Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, European Best Practice Guidelines Working Group, et al. Revised European Best Practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1–47.PubMedCrossRef
18.
Zurück zum Zitat Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):386–93.PubMedCrossRef Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):386–93.PubMedCrossRef
19.
Zurück zum Zitat Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein M. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(4):688–93.PubMedCrossRef Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein M. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(4):688–93.PubMedCrossRef
20.
Zurück zum Zitat Vanoaica L, Darshan D, Richman L, Schümann K, Kühn LC. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metab. 2010;12(3):273–82. Vanoaica L, Darshan D, Richman L, Schümann K, Kühn LC. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metab. 2010;12(3):273–82.
21.
Zurück zum Zitat Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534–40.PubMedCrossRef Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6):534–40.PubMedCrossRef
22.
Zurück zum Zitat Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood. 2007;109(7):2693–9.PubMed Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood. 2007;109(7):2693–9.PubMed
Metadaten
Titel
The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients
verfasst von
Mana Yahiro
Takahiro Kuragano
Aritoshi Kida
Rie Kitamura
Minoru Furuta
Yukiko Hasuike
Yoshinaga Otaki
Hiroshi Nonoguchi
Takeshi Nakanishi
Publikationsdatum
01.06.2012
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 3/2012
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0584-0

Weitere Artikel der Ausgabe 3/2012

Clinical and Experimental Nephrology 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.